US · Healthcare · Biotechnology
EPS came in at -1.50 against a street estimate of -1.63 — a beat of 8.0%.
Analysts rate Cytokinetics Inc a buy (18 buy, 3 hold, 0 sell out of 21) with an average price target of $109.90.
CONFIDENT MYQORZO U.S. launch exceeding expectations with 1,500 dispensed patients, >40% new-to-brand share by Q2 exit. ACACIA-HCM nHCM trial met dual primaries. sNDA filing Q4 2026. R&D/SG&A guidance raised to $860–890M. Q2 2026 U.S. net product revenue $23M (Q2); Europe $2.3M (Germany stocking, June launch). UK and Netherlands approvals/guidance post-quarter. Multiple European launches Q4 2026–H1 2027. Europe expected ~15% of overall revenue long-term. Analysts pressed conversion funnel (Rx-to-dispensed delays), share trajectory (path to 50%), and nHCM label/REMS differentiation. Management emphasized REMS/auth process duration, cross-segment depth growth, and premature to speculate on regulatory terms before sNDA submission. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| T. Rowe Price Investment Management,Inc. | 12.61% |
| BlackRock Inc | 11.90% |
| FMR Inc | 7.71% |
| Wellington Management Company LLP | 4.99% |
| Vanguard Portfolio Management, LLC | 4.20% |
| State Street Corp | 4.13% |
| Vanguard Capital Management, LLC | 3.95% |
| venBio Select Advisor LLC | 2.40% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 CYTOKINETICS, INCORPORATED – 8-K SUMMARY HEADLINE NUMBERS • Company: Cytokinetics, Incorporated (Nasdaq ticker: CYTK) • Announcement date: August 28 | 2026-08-28 |
| Company announcement · Q3 2026 CYTOKINETICS, INCORPORATED - 8-K SUMMARY HEADLINE NUMBERS • No financial data provided in this filing • Company trades on Nasdaq Global Select Market | 2026-08-13 |
| Quarterly report · Q2 2026 CYTOKINETICS, INCORPORATED – FORM 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash and investments: $1.7 billion as of June 30, | 2026-08-06 |
| Results announced · Q3 2026 CYTOKINETICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $1.7 billion in cash, cash equivalents and investments as of June 3 | 2026-08-06 |
| Shareholder vote results · Q2 2026 CYTOKINETICS, INCORPORATED – 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting Date: May 27, 2026 • Total Shares Eligible to Vote: 124,237,822 shares of | 2026-05-27 |
| Quarterly report · Q1 2026 CYTOKINETICS, INCORPORATED – FORM 10-Q SUMMARY For Quarter Ended March 31, 2026 --- HEADLINE NUMBERS • Net Loss Q1 2026: $206.0 million (vs. $161.4 | 2026-05-05 |
| Proxy statement · Q2 2026 CYTOKINETICS, INCORPORATED — 2026 PROXY STATEMENT SUMMARY --- CEO TOTAL COMPENSATION & CHANGE • CEO compensation for 2025 not explicitly stated in | 2026-04-17 |
| Annual report FY2025 CYTOKINETICS, INCORPORATED — 10-K SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Market capitalization (as of June 30, 2025): $2.5 billion in | 2026-02-26 |
Readable in the app.
| Announcement | Date |
|---|---|
| MYQORZO U.S. launch shows strong demand with 680 patients prescribed in Q1 Cytokinetics reported strong early results for MYQORZO (aficamten), its newly launched heart disease drug. In just the first quarter after its late-January U.S. launch, over 275 doctors pres | 2026-05-05 |
| Q4 2025 results reported; full year 2026 financial guidance provided Cytokinetics, a biotech company, announced FDA approval of MYQORZO (aficamten) for treating obstructive hypertrophic cardiomyopathy (oHCM) in December 2025, marking its transition to a comme | 2026-02-24 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cytokinetics Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.